NASDAQ:BIAFW

bioAffinity Technologies News Update

Retrieved on: 
Thursday, May 2, 2024
Research, Medical Devices, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Physician, Nursing care plan, ATS, Chronic obstructive pulmonary disease, Lung cancer, Bronchoalveolar lavage, Conference, Baxter International, BIAF, Lung, Patient, Pulmonology, Marketing, Empathy, BAL, American Thoracic Society, Fluid, COPD, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.
  • Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath® Lung for their patients.
  • bioAffinity Technologies’ National Sales Director Dallas Coleman announced that Jackie Kennedy has joined the Company as Pulmonary Sales Executive for CyPath® Lung in the San Antonio/Austin market.
  • “Patients have told us how much they appreciate having a Patient Coach who can walk them through the collection process,” bioAffinity Technologies President and CEO Maria Zannes said.

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

Retrieved on: 
Wednesday, April 24, 2024
Other Defense, FDA, Other Health, Radiology, Pharmaceutical, Surgery, Oncology, Medical Devices, Defense, Genetics, Military, Clinical Trials, Biotechnology, Science, Research, Health, Doctor of Philosophy, University, Chronic obstructive pulmonary disease, Lung cancer, DOD, Prognosis, University of Texas System, Artificial intelligence, Sputum, Molecular and Cellular Biology, BIAF, Lung, Patient, Principal, Observational study, Cellular senescence, New product development, Biopsy, BAMC, Bronchoalveolar lavage, BAL, COPD, Medical imaging

The second test under development analyzes sputum to improve detection of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • The second test under development analyzes sputum to improve detection of chronic obstructive pulmonary disease (COPD).
  • COPD is an inflammatory lung disease that causes breathing-related problems and irreversible airflow obstruction for an estimated 16 million Americans, according to the Centers for Disease Control.
  • Dr. Elzi earned his Ph.D. in Molecular and Cellular Biology from the University of Washington, in conjunction with the Fred Hutchinson Cancer Research Center.
  • He subsequently performed post-doctoral research at the Bonfils Blood Center and University of Colorado Department of Surgery, where he studied the molecular mechanisms of transfusion-related lung injury.

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

Retrieved on: 
Tuesday, April 9, 2024
Other Health, Research, Pharmaceutical, Philanthropy, Oncology, Medical Devices, Genetics, Foundation, Clinical Trials, Science, Biotechnology, Health, QI, Lung cancer, Survival, Partnership, Risk, American Cancer Society, Cancer, Lung, BIAF, ACS, Map, Mobile phone

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.
  • Initially launched in November 2023 to support local lung cancer screening, bioAffinity Technologies and its ACS South Region partner have expanded the geographic reach to include ACS Lung QI sites across the country.
  • The campaign highlights the value of early screening and provides information about bioAffinity Technologies’ CyPath® Lung , a noninvasive test to improve early detection of lung cancer.
  • The ACS website has an interactive map that helps people eligible for screening find a cancer screening location near them.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Retrieved on: 
Friday, March 8, 2024
Research, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, BIAF, Suite, Sale, Exercise, Regulation D, Form, Offering, Security (finance)

The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting underwriter fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting underwriter fees and other offering expenses payable by the Company.
  • The common stock was issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The common warrants will be issued in a concurrent private placement.
  • A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov .

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Retrieved on: 
Wednesday, March 6, 2024
Research, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, BIAF, Suite, Sale, Exercise, Regulation D, Form, Offering, Security (finance)

The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions.
  • The common stock will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The common warrants will be issued in a concurrent private placement.
  • A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC and available on the SEC’s website located at http://www.sec.gov .

bioAffinity Technologies News Update

Retrieved on: 
Wednesday, February 21, 2024
Oncology, Health, Biometrics, Health Technology, General Health, Biotechnology, BIAF, American Thoracic Society, Medicine, Sputum, Research, Fluid, Cole, Conference, Chronic obstructive pulmonary disease, Nursing care plan, Lung, BAL, ATS, Human, Associate, Patient, Lung cancer, Bronchoalveolar lavage, COPD, Evidence-based practice, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Lung Innovations Network’s multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice.
  • National Sales Director Dallas Coleman announced that Cole Koeppen has joined bioAffinity Technologies as Pulmonary Sales Executive for CyPath® Lung in North Texas.
  • Bansal’s experience as both clinician and researcher demonstrates his commitment to innovative healthcare and the best possible outcome for his patients,” bioAffinity Technologies President and CEO Maria Zannes said.

bioAffinity Technologies In The News

Retrieved on: 
Tuesday, January 30, 2024
Technology, Surgery, Medical Devices, General Health, Science, Genetics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Software, Other Health, Radiology, Pharmaceutical, Oncology, Intelligence, Lung cancer, College, Therapy, Clinical Laboratory, Sputum, CLIA, BIAF, Laboratory, Artificial intelligence, TCPP, Patent, Lung, Accreditation, CAP, Porphyrin, Cancer, Malignancy, Medical imaging

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Precision Pathology Laboratory Services (PPLS), a bioAffinity Technologies company, successfully passed the rigorous biannual inspection required for College of American Pathologists (CAP) accreditation.
  • ScienceSoft , which provides IT consulting and software development services to more than 1,200 clients around the globe, recently published a case study of its work with bioAffinity Technologies.
  • More than 1,000 people registered for Webull Corporate Connect’s recent investment webinar that featured bioAffinity Technologies ’ President and CEO Maria Zannes and two other healthcare executives.

bioAffinity Technologies In the News

Retrieved on: 
Monday, January 8, 2024
Medical Supplies, Biotechnology, Managed Care, Other Health, Health, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, American Medical Association, American Cancer Society, Caregiver, Physician, Lung cancer, National Association, News, BIAF, University, Ecosystem, Bloomberg Television, Medicare, Lung, CPT, Patient, Organization, Veterans' affairs, CMS

bioAffinity Technologies (BIAF) and CyPath® Lung Featured on Bloomberg TV, National Podcasts and Upcoming Webinar

Key Points: 
  • bioAffinity Technologies (BIAF) and CyPath® Lung Featured on Bloomberg TV, National Podcasts and Upcoming Webinar
    bioAffinity Technologies ’ President and CEO Maria Zannes was recently featured on “Small Stocks, Big Money™” on Bloomberg TV .
  • Craig Brelsford with RedChip Companies interviewed Maria about bioAffinity Technologies’ advancements in the medical field, including commercialization of CyPath® Lung, a noninvasive test for the early detection of lung cancer.
  • Learn more about bioAffinity Technologies by registering for the RedChip webinar with Maria to take place via Zoom on Tuesday, Jan. 9, at 4:15 p.m.
  • bioAffinity Technologies joined the American Cancer Society and University of Texas Health San Antonio to raise awareness and funding for lung cancer screening, showing that when we work together, lung cancer screening programs are a success.

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Surgery, Artificial Intelligence, Oncology, Research, Medical Devices, Genetics, Health Technology, Science, Clinical Trials, Liquid biopsy, Lung, BIAF, NeoGenomics, Labcorp, Genomics, Quest Diagnostics, Genomics England, Lung cancer, Roche, Growth, NGS, Hospital, Management

Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets.

Key Points: 
  • Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets.
  • Under her leadership, the company raised a Series A funding and enhanced the board with expertise from U.S. and international markets.
  • "I am deeply honored to join the bioAffinity Technologies Board of Directors," Dr. Platt said.
  • Dr. Platt replaces Mohsin Y. Meghji who stepped down from the Board of Directors on Dec. 1, 2023, after serving four years.